Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPR1 | P16066 | 20/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28726534 | 0.91 | NPR1 (0.58) | NPR1 | |
| SCHEMBL22715109 | 0.79 | NPR1 (0.48) | NPR1 | |
| SCHEMBL29543921 | 0.79 | NPR1 (0.48) | NPR1 | |
| SCHEMBL4349736 | 0.78 | NPR1 (0.56) | NPR1 | |
| SCHEMBL29232599 | 0.76 | NPR1 (0.49) | NPR1 | |
| SCHEMBL22745095 | 0.76 | NPR1 (0.44) | NPR1 | |
| SCHEMBL4367513 | 0.74 | NPR1 (0.55) | NPR1 | |
| SCHEMBL4349987 | 0.73 | NPR1 (0.54) | NPR1 | |
| SCHEMBL4363691 | 0.71 | GABBR2 (0.50) | NPR1 | |
| SCHEMBL4352010 | 0.69 | GABBR2 (0.68) | NPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118239931-A | As P2X3Aminoquinazoline derivatives of inhibitors | 奇斯药制品公司 | 2024-06-25 | — | — | CN | claimed |
| CN-114269432-B | As P2X3Aminoquinazoline derivatives of inhibitors | 奇斯药制品公司 | 2024-05-07 | — | — | CN | claimed |
| EP-3976179-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2022-04-06 | — | — | EP | claimed |
| CN-114269432-A | As P2X3Aminoquinazoline derivatives as inhibitors | 奇斯药制品公司 | 2022-04-01 | — | — | CN | claimed |
| US-12637451-B2 | Amino quinazoline derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-05-26 | — | — | US | disclosed |
| US-20230092892-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2023-03-23 | — | — | US | disclosed |
| WO-2020239951-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092892-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | NPR1 157/4885 |
| US-12637451-B2 | Amino quinazoline derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX7 | NPR1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.